Literature DB >> 26820355

Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF).

Michael Fu1, Jingmin Zhou2, Erik Thunström3, Torbjörn Almgren4, Ludger Grote5, Entela Bollano6, Maria Schaufelberger3, Magnus C Johansson7, Max Petzold8, Karl Swedberg9, Bert Andersson6.   

Abstract

AIMS: The pathophysiology of heart failure with preserved ejection fraction (HFPEF) is not fully understood. A recently proposed mechanism for HFPEF is that it is a systemic pro-inflammatory state induced by comorbidities, leading to microvascular endothelial dysfunction and subsequent cardiac remodeling and dysfunction. We hypothesize that targeting comorbidities will improve outcomes in elderly patients with HFPEF. Thus, the aim of this study is to determine whether the combination of systematic screening and optimal management of prespecified comorbidities associated with HFPEF improves outcomes.
METHODS: This multicenter, prospective, randomized intervention trial uses an open procedure with blinded endpoint assessment. Patients with HFPEF aged >60 years (n = 360) will be randomized 1:1 to the usual care or intervention arm of the trial. When randomized to the intervention arm, all patients will be systematically screened and optimally treated for the most frequent cardiovascular, metabolic, respiratory, and renal comorbidities. The primary endpoint is a composite clinical score that classifies each randomized patient as improved or deteriorated based on objective and subjective data at a 24-month follow-up performed by a blinded endpoint committee.
CONCLUSION: Rather than targeting cardiac dysfunction, our study aims to present evidence for a possible paradigm shift in the management of HFPEF. Our novel concept focuses on the management of comorbidities as predisposing factors in HFPEF.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HFPEF; Heart failure; comorbidity; management; mortality

Mesh:

Year:  2016        PMID: 26820355     DOI: 10.1016/j.cardfail.2016.01.011

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  12 in total

Review 1.  The American Heart Association Heart Failure Summit, Bethesda, April 12, 2017.

Authors:  Pamela N Peterson; Larry A Allen; Paul A Heidenreich; Nancy M Albert; Ileana L Piña
Journal:  Circ Heart Fail       Date:  2018-10       Impact factor: 8.790

Review 2.  Medical Therapy for Heart Failure Caused by Ischemic Heart Disease.

Authors:  Islam Y Elgendy; Dhruv Mahtta; Carl J Pepine
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 3.  Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?

Authors:  Sergio Caravita; Jean-Luc Vachiéry
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 4.  Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions.

Authors:  Bharathi Upadhya; Mark J Haykowsky; Dalane W Kitzman
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

5.  Reduced Myocardial Flow Reserve Is Associated With Diastolic Dysfunction and Decreased Left Atrial Strain in Patients With Normal Ejection Fraction and Epicardial Perfusion.

Authors:  Matthew C Konerman; Joshua C Greenberg; Theodore J Kolias; James R Corbett; Ravi V Shah; Venkatesh L Murthy; Scott L Hummel
Journal:  J Card Fail       Date:  2017-10-16       Impact factor: 5.712

6.  A Gordian knot: disentangling comorbidities in heart failure.

Authors:  Nancy Luo; Robert J Mentz
Journal:  Eur J Heart Fail       Date:  2016-07-04       Impact factor: 15.534

7.  Echocardiographic subtypes of heart failure in consecutive hospitalised patients with dyspnoea.

Authors:  Olav Wendelboe Nielsen; Nana Valeur; Ahmad Sajadieh; Andreas Fabricius-Bjerre; Christian Malchau Carlsen; Lars Kober
Journal:  Open Heart       Date:  2019-06-20

8.  Stress echocardiography for left ventricular diastolic dysfunction detection in patients with non-severe chronic obstructive pulmonary disease: a cross-sectional study.

Authors:  Radostina Vl Cherneva; Mariana V Gospodinova; Stefan V Denchev; Rosen B Petkov; Dimitar E Kostadinov; Zheina Vl Cherneva
Journal:  Croat Med J       Date:  2019-10-31       Impact factor: 1.351

9.  Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction.

Authors:  Akiomi Yoshihisa; Yu Sato; Tetsuro Yokokawa; Takamasa Sato; Satoshi Suzuki; Masayoshi Oikawa; Atsushi Kobayashi; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Shu-Ichi Saitoh; Yasuchika Takeishi
Journal:  ESC Heart Fail       Date:  2017-10-02

10.  Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.

Authors:  Marta Michalska-Kasiczak; Agata Bielecka-Dabrowa; Stephan von Haehling; Stefan D Anker; Jacek Rysz; Maciej Banach
Journal:  Arch Med Sci       Date:  2018-06-11       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.